دورية أكاديمية
Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.
| العنوان: | Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma. |
|---|---|
| المؤلفون: | Rezagholizadeh F; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran., Tajik F; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran., Talebi M; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.; Human and Animal Cell Bank, Iranian Biological Resource Center (IBRC), Tehran, Iran., Taha SR; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran., Shariat Zadeh M; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran., Farhangnia P; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Tehran, Iran.; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran., Hosseini HS; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran., Nazari A; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran., Mollazadeh Ghomi S; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Immunology Board for Transplantation and Cell-Based Therapeutics (ImmunoTACT), Universal Scientific Education and Research Network (USERN), Tehran, Iran.; Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran., Kamrani Mousavi SM; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran., Haeri Moghaddam N; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran., Khorramdelazad H; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.; Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran., Joghataei MT; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran., Safari E; Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.; Immunology Research Center, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Jan 30; Vol. 15, pp. 1283364. Date of Electronic Publication: 2024 Jan 30 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Carcinoma, Pancreatic Ductal*/diagnosis , Carcinoma, Pancreatic Ductal*/genetics , Carcinoma, Pancreatic Ductal*/metabolism , Pancreatic Neoplasms*/diagnosis , Pancreatic Neoplasms*/genetics , Pancreatic Neoplasms*/metabolism, Humans ; CD8-Positive T-Lymphocytes ; Prognosis ; Transcription Factors ; CD8 Antigens/metabolism |
| مستخلص: | Introduction: Pancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer. Methods: We analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of normal pancreatic tissue to assess the expression levels of the markers. We then correlated these expression levels with the clinicopathological characteristics of the patients and evaluated their survival rates. Results: The analysis of the GEO data revealed slightly elevated levels of VISTA in PDAC samples compared to normal tissues. However, there was a significant increase in CD68 expression and a notable reduction in CD8A expression in pancreatic cancer. Further investigation identified potential protein-protein interactions and transcription factors associated with these markers. The IHC staining of PDAC tissue samples showed an increased expression of VISTA, CD68, and CD8A in pancreatic cancer tissues. Moreover, we found correlations between the expression levels of these markers and certain clinicopathological features of the patients. Additionally, the survival analysis revealed that high expression of CD8 was associated with better disease-specific survival and progression-free survival in PDAC patients. Conclusion: These findings highlight the potential of CD8, CD68, and VISTA as diagnostic and prognostic indicators in PDAC. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Rezagholizadeh, Tajik, Talebi, Taha, Shariat Zadeh, Farhangnia, Hosseini, Nazari, Mollazadeh Ghomi, Kamrani Mousavi, Haeri Moghaddam, Khorramdelazad, Joghataei and Safari.) |
| References: | Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. (PMID: 29203588) Int Immunopharmacol. 2021 Jun;95:107508. (PMID: 33725635) J Hematol Oncol. 2020 Jun 29;13(1):83. (PMID: 32600443) Cancer Immunol Immunother. 2021 Nov;70(11):3113-3122. (PMID: 33770210) Front Oncol. 2022 Jul 28;12:951019. (PMID: 35965504) N Engl J Med. 2022 Jun 23;386(25):2363-2376. (PMID: 35660797) Oncoimmunology. 2021 Apr 7;10(1):1907059. (PMID: 33889438) J Clin Med. 2023 Feb 17;12(4):. (PMID: 36836154) Sci Rep. 2021 Nov 2;11(1):21504. (PMID: 34728682) Cancer Immunol Res. 2014 Jun;2(6):510-7. (PMID: 24894088) BMJ Open. 2017 Dec 26;7(12):e018175. (PMID: 29282264) Front Med (Lausanne). 2022 Feb 10;9:790995. (PMID: 35223897) Oral Oncol. 2016 Jun;57:54-60. (PMID: 27208845) Int J Mol Sci. 2021 Jun 29;22(13):. (PMID: 34209703) Oncol Lett. 2018 May;15(5):6217-6224. (PMID: 29616104) Front Oncol. 2022 Apr 06;12:851191. (PMID: 35463322) Ann Surg Oncol. 2018 Apr;25(4):845-847. (PMID: 28752469) Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697. (PMID: 30635425) BMC Cancer. 2018 May 2;18(1):511. (PMID: 29720116) Clin Exp Immunol. 2020 May;200(2):120-130. (PMID: 31930484) Front Oncol. 2018 Jul 13;8:269. (PMID: 30057891) Trends Cancer. 2018 Jun;4(6):418-428. (PMID: 29860986) Front Immunol. 2017 Sep 07;8:1097. (PMID: 28936211) Aging (Albany NY). 2021 Jan 10;13(3):3386-3404. (PMID: 33428605) Front Immunol. 2023 May 11;14:1174138. (PMID: 37251372) Mol Biotechnol. 2024 Jan;66(1):138-150. (PMID: 37060513) Cancers (Basel). 2023 Apr 17;15(8):. (PMID: 37190254) CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) Clin Chim Acta. 2013 Mar 15;418:22-9. (PMID: 23305796) Protein Cell. 2019 Nov;10(11):840-845. (PMID: 31236852) Front Oncol. 2021 Jan 11;10:583966. (PMID: 33505908) J Immunother. 2021 Jan;44(1):22-28. (PMID: 33086339) Medicine (Baltimore). 2019 Jan;98(2):e13923. (PMID: 30633166) Pharmaceuticals (Basel). 2022 Mar 09;15(3):. (PMID: 35337133) Expert Rev Clin Immunol. 2022 Dec;18(12):1217-1237. (PMID: 36154551) Exp Ther Med. 2019 Dec;18(6):4490-4498. (PMID: 31777551) Front Immunol. 2020 Oct 29;11:563044. (PMID: 33250890) BMC Cancer. 2019 Sep 14;19(1):920. (PMID: 31521128) Sci Rep. 2020 Sep 1;10(1):14372. (PMID: 32873829) Open Access Maced J Med Sci. 2018 Mar 02;6(3):435-441. (PMID: 29610597) Clin Cancer Res. 2017 Jun 15;23(12):3129-3138. (PMID: 28007776) Cancer Immunol Res. 2019 Sep;7(9):1497-1510. (PMID: 31340983) Cancer Res. 2014 Jun 1;74(11):2913-21. (PMID: 24840647) Br J Cancer. 2021 Jan;124(2):359-367. (PMID: 32929195) Histopathology. 2019 Sep;75(3):421-430. (PMID: 31013360) Cell Res. 2017 Jan;27(1):11-37. (PMID: 28025978) Mod Pathol. 2019 Oct;32(10):1495-1507. (PMID: 31186528) Cancer Immunol Res. 2023 Jan 3;11(1):38-55. (PMID: 36260656) Oncoimmunology. 2019 Feb 27;8(5):e1581546. (PMID: 31069143) Cancer Treat Res Commun. 2023;35:100699. (PMID: 36996584) Front Immunol. 2019 Nov 19;10:2641. (PMID: 31803182) Nat Med. 2017 May;23(5):551-555. (PMID: 28346412) Int J Mol Sci. 2020 Jun 23;21(12):. (PMID: 32586046) Br J Cancer. 2019 Jan;120(1):115-127. (PMID: 30382166) Cancers (Basel). 2021 May 29;13(11):. (PMID: 34072549) J Exp Med. 1995 Aug 1;182(2):459-65. (PMID: 7543139) Cancers (Basel). 2022 Jun 30;14(13):. (PMID: 35805011) Front Oncol. 2022 Sep 08;12:961374. (PMID: 36158663) PLoS One. 2014 May 02;9(5):e96565. (PMID: 24794217) BMC Cancer. 2021 Dec 7;21(1):1305. (PMID: 34876062) PLoS One. 2014 May 05;9(5):e94357. (PMID: 24797069) J Hematol Oncol. 2021 Mar 19;14(1):45. (PMID: 33741032) Clin Cancer Res. 2020 Sep 15;26(18):4814-4822. (PMID: 32554514) Bosn J Basic Med Sci. 2022 Sep 16;22(5):707-715. (PMID: 35122478) Int J Mol Sci. 2023 Jan 21;24(3):. (PMID: 36768480) Biomedicines. 2022 Jul 21;10(7):. (PMID: 35885065) Hum Pathol. 2021 Jul;113:20-27. (PMID: 33887301) Oncol Lett. 2022 Dec 08;25(1):39. (PMID: 36589661) J Cancer Res Clin Oncol. 2021 Feb;147(2):517-531. (PMID: 33237432) Oncogenesis. 2018 Dec 19;7(12):97. (PMID: 30563983) World J Gastroenterol. 2021 Jul 21;27(27):4298-4321. (PMID: 34366606) Front Immunol. 2023 Jun 27;14:1155778. (PMID: 37441075) J Clin Oncol. 2022 Aug 20;40(24):2789-2805. (PMID: 35839445) Acta Neuropathol Commun. 2023 Apr 15;11(1):64. (PMID: 37061716) Cancer Immunol Immunother. 2017 May;66(5):627-636. (PMID: 28236118) Sci Rep. 2020 Feb 14;10(1):2662. (PMID: 32060343) Oncoimmunology. 2017 Feb 21;6(4):e1293215. (PMID: 28507801) Open Access Maced J Med Sci. 2015 Jun 15;3(2):209-14. (PMID: 27275223) Future Oncol. 2016 Aug;12(16):1929-46. (PMID: 27246628) J Immunother. 2010 Oct;33(8):828-33. (PMID: 20842054) J Infect Public Health. 2023 Apr;16(4):542-550. (PMID: 36801634) PLoS One. 2017 Dec 8;12(12):e0188591. (PMID: 29220404) Cancers (Basel). 2021 Aug 23;13(16):. (PMID: 34439389) Science. 2020 Jan 17;367(6475):. (PMID: 31949051) Sci Rep. 2022 May 12;12(1):7844. (PMID: 35550532) Cancers (Basel). 2021 Feb 13;13(4):. (PMID: 33668519) Cancer Res. 2014 Apr 1;74(7):1933-44. (PMID: 24691994) J Hematol Oncol. 2022 Aug 17;15(1):111. (PMID: 35978433) Cancers (Basel). 2021 Aug 19;13(16):. (PMID: 34439315) Cancer Immunol Immunother. 2018 Jul;67(7):1113-1121. (PMID: 29737375) Oncotarget. 2016 Nov 8;7(45):72819-72832. (PMID: 27637082) Life (Basel). 2022 Aug 13;12(8):. (PMID: 36013407) PLoS One. 2023 Mar 23;18(3):e0278849. (PMID: 36952478) Cancers (Basel). 2022 Jan 03;14(1):. (PMID: 35008381) Am J Transl Res. 2021 Sep 15;13(9):10428-10438. (PMID: 34650712) JAMA Oncol. 2019 Oct 01;5(10):1431-1438. (PMID: 31318392) Cancer Immunol Immunother. 2018 Nov;67(11):1685-1694. (PMID: 30128738) Cancer Microenviron. 2013 Aug;6(2):123-33. (PMID: 23242673) Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. (PMID: 25964334) |
| فهرسة مساهمة: | Keywords: CD68; CD8; PDAC; VISTA; biomarker; pancreatic ductal adenocarcinoma; prognosis |
| المشرفين على المادة: | 0 (Transcription Factors) 0 (VSIR protein, human) 0 (CD8 Antigens) 0 (CD68 antigen, human) |
| تواريخ الأحداث: | Date Created: 20240215 Date Completed: 20240221 Latest Revision: 20240327 |
| رمز التحديث: | 20240329 |
| مُعرف محوري في PubMed: | PMC10865497 |
| DOI: | 10.3389/fimmu.2024.1283364 |
| PMID: | 38357542 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1283364 |